BioStem Technologies

How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond
Sponsored
BioStem Reveals Plans For New Products, Expanded Sales And Manufacturing Capabilities At Dawson James Small Cap Growth Conference
Sponsored
Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care
Sponsored
BioStem Reveals Plans For New Products, Expanded Sales And Manufacturing Capabilities At Dawson James Small Cap Growth Conference
Sponsored
Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care
Sponsored
2022 Year in Review: BioStem Technologies Looks Back At A Year of Growth And Expansion
Sponsored
BioStem Aims To Stay Ahead Of Competition Through Its Unique Processes And Versatile Offerings In Wound Healing
Sponsored

BioStem Technologies Recent News

Could Perinatal Allografts Be Charting A New Course In Wound Healing?
An allograft is tissue that is transplanted from one person to another. The prefix “allo” comes from a Greek word meaning “other.” An allograft is different from an autograft, which uses the individual's own tissue and is, therefore, genetically identical.
Sponsored
BioStem Technologies (OTCMKTS: BSEM) Coverage Initiated at Zacks Investment Research
The below report was authored by Brad Sorensen, CFA, Zacks Small Cap Research. You can find the original report here.  
Sponsored
BioStem Technologies, Inc. Second Quarter Financial Results Call, August 22, 2022
C O R P O R A T E   P A R T I C I P A N T S Nicolas Johnson, Russo Partners Jason Matuszewski, Chief Executive Officer Michael Fortunato, Controller C O N F E R E N C E   C A L L   P A R T I C I P A N T S
Sponsored
BioStem Technologies Reports 133% Year-Over-Year Revenue Growth As It Expands Distribution of Patented Allograft Tech
BioStem Technologies Inc. (OTCMKTS: BSEM) is a regenerative medicine company that develops and manufactures tissue allografts for use in surgery and wound care. In August, the company reported growth exceeding even its own expectations as net revenue increased to $2.2 million for the second quarter.
Sponsored
BioStem Technologies' Local MicroEnvironment Activation Possible Key To Reversing And Repairing Diseases-Caused Tissue Damage
Jason Matuszewski, CEO of BioStem Technologies Inc. (OTCMKTS: BSEM), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 
Sponsored